Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors

Immuno-oncology is an ever growing field that has seen important progress across the spectrum of cancers. Responses can be deep and durable. However, as only a minority of patients respond to checkpoint inhibition, predictive biomarkers are needed. Cancer is a genetic disease arising from the accumu...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlaender, Alex, Nouspikel, Thierry, Christinat, Yann, Ho, Liza, McKee, Thomas, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028749/
https://www.ncbi.nlm.nih.gov/pubmed/32117779
http://dx.doi.org/10.3389/fonc.2020.00142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028749/
https://www.ncbi.nlm.nih.gov/pubmed/32117779
http://dx.doi.org/10.3389/fonc.2020.00142

Ejemplares similares